These extracts demonstrated highly efficient activity in K-562 human chronic myeloid leukemia (CML) and BV-173 human B cell precursor leukemia (Philadelphia chromosome-positive cell lines, bearing t(9;22) BCR-ABL1 fusion gene); T-24 human urinary bladder carcinoma and HT-29 human colon adenocarcinoma cell lines. This evidence concerns the gene ABL1 and colon adenocarcinoma.